Okimoto, Ross A <br/><br/>
Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.  [electronic resource] 

 -  Proceedings of the National Academy of Sciences of the United States of America  11 2016 
 - 13456-13461 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1091-6490 
<br/><br/><label>Standard No.: </label>10.1073/pnas.1610456113  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Cell Line, Tumor<br/>Drug Resistance, Neoplasm--drug effects<br/>Enzyme Activation--drug effects<br/>Female<br/>Gene Knockdown Techniques<br/>Heterocyclic Compounds, 2-Ring--adverse effects<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>MAP Kinase Signaling System--drug effects<br/>Mechanistic Target of Rapamycin Complex 1--metabolism<br/>Mice, SCID<br/>Mutation--genetics<br/>Protein Kinase Inhibitors--pharmacology<br/>Proto-Oncogene Mas<br/>Proto-Oncogene Proteins B-raf--antagonists & inhibitors<br/>Sulfonamides--adverse effects<br/>Treatment Outcome